(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 165.03% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Liquidia's revenue in 2025 is $19,322,000.On average, 3 Wall Street analysts forecast LQDA's revenue for 2025 to be $4,655,825,832, with the lowest LQDA revenue forecast at $4,258,944,229, and the highest LQDA revenue forecast at $4,864,167,151. On average, 3 Wall Street analysts forecast LQDA's revenue for 2026 to be $19,798,451,676, with the lowest LQDA revenue forecast at $11,595,657,939, and the highest LQDA revenue forecast at $24,569,640,057.
In 2027, LQDA is forecast to generate $30,968,473,467 in revenue, with the lowest revenue forecast at $18,121,390,152 and the highest revenue forecast at $41,031,186,976.